查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1433535

肝轉移治療市場規模、佔有率、趨勢分析報告：依治療類型、原發癌症、通路、地區、細分市場預測，2024-2030

Liver Metastases Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Chemotherapy, Immunotherapy), By Primary Cancer, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

肝轉移治療市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球肝轉移治療市場預計將達到26.6億美元，2024年至2030年複合年成長率為7.3%。

目標疾病盛行率的上升、開發中國家癌症的晚期診斷以及產品核可數量的增加預計將推動該行業的成長。

大腸、乳癌和肺癌是轉移至肝臟的一些主要癌症類型。大腸發生率預計將從2020年的188萬人增加到2030年的245萬人。同時，乳癌發生率預計將從2020年的226萬人增加到2030年的274萬人。這些關鍵適應症的日益普及預計將推動市場成長。

低收入和中等收入國家的大多數癌症患者在診斷時已處於晚期，此時治療方案較少。無法取得早期診斷方法和診斷報銷情況不確定是診斷延誤的主要原因。診斷的晚期/轉移階段為該領域提供了利潤豐厚的成長機會。

另一方面，特別是在開發中國家和中低收入國家，由於缺乏產品和足夠的報銷，即使在癌症晚期才被診斷出來，晚期治療率也明顯較低。預計這些因素將抑制市場成長。

肝轉移治療市場報告亮點

  • 從治療類型來看，標靶治療市場主導地位，其核准的藥物價格高於常規化療，市佔率為56.52%。
  • 2023年，大腸直腸癌以40.55%的佔有率主導肝轉移治療市場。約 25-30% 的大腸轉移至肝臟。 CCLM 的各種治療方案的可用性進一步增強了該細分市場的主導地位。
  • 從分銷管道來看，醫院藥房細分市場佔據主導地位，2023年佔有率為60.07%。肝轉移治療的高住院率是導致該細分市場佔據主導地位的主要因素之一。
  • 按地區分類，2023年北美將在全球肝轉移治療市場中佔據最高收益佔有率。然而，亞太地區預計將成為預測期內成長最快的地區。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章肝轉移治療市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
  • 治療類型普及與成長前景圖，2023 年
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 市場分析工具
    • 產業分析：波特五力分析
    • 產業分析：PESTEL

第 4 章 肝轉移治療市場：2018-2030 年按治療類型細分分析（百萬美元）

  • 肝轉移治療市場：治療類型變化分析

第5章肝轉移治療市場：依原發癌症細分分析，2018-2030（百萬美元）

  • 肝轉移治療市場：原發癌症變化分析

第6章 肝轉移治療市場：依銷售管道細分分析，2018-2030（百萬美元）

  • 肝轉移治療市場：通路波動分析

第7章肝轉移治療市場：按類型、產品和應用分類的區域估計和趨勢分析

  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲 (MEA)

第8章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
    • New product launch
    • Merger and acquisition
    • Licensing agreements
    • Conferences and campaigns
  • 公司分類
    • 創新者
    • 市場領導者
  • 供應商形勢
    • List of key distributors and channel partners
    • Key customers
  • 上市公司
    • 2023年主要企業市場佔有率分析
    • 公司市場分析
    • 熱圖分析
    • 競爭儀表板分析
  • 私人公司
    • 主要新興企業名單
    • 區域網路圖
  • 公司簡介
    • F. Hoffmann-La Roche Ltd.
    • AstraZeneca
    • Bayer AG
    • Eli Lilly and Company
    • Ono Pharmaceutical
    • Pfizer, Inc.
    • Bristol-Myers Squibb Company
    • Cadila Pharmaceuticals Ltd.
Product Code: GVR-4-68040-034-2

Liver Metastases Treatment Market Growth & Trends:

The global liver metastases treatment market is expected to reach USD 2.66 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 7.3% from 2024 to 2030. Rising prevalence of target disease, advanced stage diagnosis for cancer in developing countries, and increasing number of products approvals is expected to drive the industry growth.

Colorectal cancer, breast cancer, and lung cancer are some of the key types that metastasize to the liver. The incidence of colorectal cancer is expected to increase from 1.88 million in 2020 to 2.45 million in 2030. Whereas the incidence of breast cancer is expected to increase from 2.26 million in 2020 to 2.74 million in 2030. The rising incidence of these primary indications is expected to drive space growth.

Majority of the cancer cases in low and middle-income countries are diagnosed at advanced stages where the availability of therapeutic options is low. The lack of availability of early diagnostics methods combined with uncertain reimbursement scenario for diagnostics are major reasons for delayed diagnosis. The advanced/metastatic stage of diagnosis provide lucrative growth opportunities in this space.

On the other hand, if cancers are diagnosed at advanced stages particularly in developing nations and LMICS, the treatment rate at such advanced stages is significantly less, due to unavailability of products and proper reimbursement. This factor is expected to restrain space growth.

Liver Metastases Treatment Market Report Highlights:

  • By treatment type, the targeted therapy segment dominated the market with a share of 56.52% to the presence of approved drugs with a price higher than traditional chemotherapy.
  • In 2023, colorectal cancer dominated the liver metastases treatment market with a share of 40.55%. Around 25-30% of all colorectal cancers metastasize to the liver. The availability of various treatment options for CCLM further contributed to the segments' dominance.
  • Based on distribution channel, the market was dominated by the hospital pharmacies segment with a share of 60.07% in 2023. The high rate of hospitalization for the treatment of liver metastases is one of the major factors for the dominance of this segment.
  • By region, North America has a high revenue share in the global liver metastases treatment market in 2023. However, Asia Pacific is expected to be the fastest growing region during the forecast period.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Regional scope
    • 1.1.2 Estimates and forecast timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database
    • 1.3.2 GVR's internal database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity flow analysis (Model 1)
      • 1.6.1.1 Approach 1: Commodity flow approach
  • 1.7 Research Assumptions
  • 1.8 List of Secondary Sources
  • 1.9 List of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective 1
    • 1.10.2 Objective 2
    • 1.10.3 Objective 3
    • 1.10.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Competitive Landscape Snapshot

Chapter 3 Liver Metastases treatment Market Variables, Trends, and Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
      • 3.1.1.1 Liver cancer treatment market
  • 3.2 Penetration and Growth Prospect Mapping for Treatment Type, 2023
  • 3.3 Market Dynamics
    • 3.3.1 Market driver analysis
      • 3.3.1.1 Approval of targeted therapy for the treatment of liver metastases
    • 3.3.2 Market restraint analysis
      • 3.3.2.1 Technological advancements for early diagnosis of cancer
  • 3.4 Market Analysis Tools
    • 3.4.1 Industry analysis: porter's
      • 3.4.1.1 Threat of new entrants
      • 3.4.1.2 Bargaining power of buyers
      • 3.4.1.3 Competitive rivalry
      • 3.4.1.4 Threat of substitutes
      • 3.4.1.5 Bargaining power of suppliers
    • 3.4.2 Industry analysis: PESTEL
      • 3.4.2.1 Political & Legal
      • 3.4.2.2 Economical
      • 3.4.2.3 Technological

Chapter 4 Liver Metastases treatment Market: Segment Analysis, by Treatment Type, 2018 - 2030 (USD Million)

  • 4.1 Liver Metastases treatment Market: Treatment Type Movement Analysis
    • 4.1.1 Chemotherapy
      • 4.1.1.1 Chemotherapy market estimates and forecast, 2018 - 2030 (USD million)
    • 4.1.2 Targeted Therapy
      • 4.1.2.1 Targeted therapy market estimates and forecast, 2018 - 2030 (USD million)
    • 4.1.3 Immunotherapy
      • 4.1.3.1 Immunotherapy market estimates and forecast, 2018 - 2030 (USD million)

Chapter 5 Liver Metastases Treatment Market: Segment Analysis, by Primary Cancer, 2018 - 2030 (USD Million)

  • 5.1 Liver Metastases treatment Market: Primary Cancer Movement Analysis
    • 5.1.1 Colorectal cancer
      • 5.1.1.1 Colorectal cancer market estimates and forecast, 2018 - 2030 (USD million)
    • 5.1.2 Breast Cancer
      • 5.1.2.1 Breast cancer market estimates and forecast, 2018 - 2030 (USD million)

Chapter 6 Liver Metastases treatment Market: Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

  • 6.1 Liver Metastases treatment Market: Distribution Channel Movement Analysis
    • 6.1.1 Hospital Pharmacies
      • 6.1.1.1 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD million)
    • 6.1.2 Specialty pharmacies
      • 6.1.2.1 Specialty pharmacies market estimates and forecast, 2018 - 2030 (USD million)

Chapter 7 Liver Metastases treatment Market: Regional Estimates and Trend Analysis, by Type, Product, & Application

  • 7.1 North America
    • 7.1.1 SWOT analysis
      • 7.1.1.1 North america liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.1.2 U.S.
      • 7.1.2.1 Key country dynamics
      • 7.1.2.2 Target disease prevalence
      • 7.1.2.3 Competitive scenario
      • 7.1.2.4 Regulatory framework
      • 7.1.2.5 Reimbursement scenario
      • 7.1.2.6 U.S. Liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.1.3 Canada
      • 7.1.3.1 Key country dynamics
      • 7.1.3.2 Target disease prevalence
      • 7.1.3.3 Competitive scenario
      • 7.1.3.4 Regulatory framework
      • 7.1.3.5 Reimbursement scenario
      • 7.1.3.6 Canada liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.2 Europe
    • 7.2.1 SWOT analysis:
      • 7.2.1.1 Europe liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.2.2 Germany
      • 7.2.2.1 Key country dynamics
      • 7.2.2.2 Target disease prevalence
      • 7.2.2.3 Competitive scenario
      • 7.2.2.4 Regulatory framework
      • 7.2.2.5 Reimbursement scenario
      • 7.2.2.6 Germany Liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.2.3 UK
      • 7.2.3.1 Key country dynamics
      • 7.2.3.2 Target disease prevalence
      • 7.2.3.3 Competitive scenario
      • 7.2.3.4 Regulatory Framework
      • 7.2.3.5 Reimbursement Scenario
      • 7.2.3.6 UK liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.2.4 France
      • 7.2.4.1 Key country dynamics
      • 7.2.4.2 Target disease prevalence
      • 7.2.4.3 Competitive scenario
      • 7.2.4.4 Regulatory framework
      • 7.2.4.5 Reimbursement scenario
      • 7.2.4.6 France liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.2.5 Italy
      • 7.2.5.1 Key country dynamics
      • 7.2.5.2 Target disease prevalence
      • 7.2.5.3 Competitive scenario
      • 7.2.5.4 Regulatory framework
      • 7.2.5.5 Reimbursement scenario
      • 7.2.5.6 Italy liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.2.6 Spain
      • 7.2.6.1 Key country dynamics
      • 7.2.6.2 Target disease prevalence
      • 7.2.6.3 Competitive scenario
      • 7.2.6.4 Regulatory framework
      • 7.2.6.5 Reimbursement scenario
      • 7.2.6.6 Spain liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.2.7 Denmark
      • 7.2.7.1 Key country dynamics
      • 7.2.7.2 Target disease prevalence
      • 7.2.7.3 Competitive scenario
      • 7.2.7.4 Regulatory framework
      • 7.2.7.5 Reimbursement scenario
      • 7.2.7.6 Denmark liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.2.8 Sweden
      • 7.2.8.1 Key country dynamics
      • 7.2.8.2 Target disease prevalence
      • 7.2.8.3 Competitive scenario
      • 7.2.8.4 Regulatory framework
      • 7.2.8.5 Reimbursement scenario
      • 7.2.8.6 Sweden liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.2.9 Norway
      • 7.2.9.1 Key country dynamics
      • 7.2.9.2 Target disease prevalence
      • 7.2.9.3 Competitive scenario
      • 7.2.9.4 Regulatory framework
      • 7.2.9.5 Reimbursement scenario
      • 7.2.9.6 Norway liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.3 Asia Pacific
    • 7.3.1 SWOT analysis:
      • 7.3.1.1 Asia Pacific liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.3.2 Japan
      • 7.3.2.1 Key country dynamics
      • 7.3.2.2 Target disease prevalence
      • 7.3.2.3 Competitive scenario
      • 7.3.2.4 Regulatory framework
      • 7.3.2.5 Reimbursement scenario
      • 7.3.2.6 Japan liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.3.3 China
      • 7.3.3.1 Key country dynamics
      • 7.3.3.2 Target disease prevalence
      • 7.3.3.3 Competitive scenario
      • 7.3.3.4 Regulatory framework
      • 7.3.3.5 Reimbursement scenario
      • 7.3.3.6 China liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.3.4 India
      • 7.3.4.1 Key country dynamics
      • 7.3.4.2 Target disease prevalence
      • 7.3.4.3 Competitive scenario
      • 7.3.4.4 Regulatory framework
      • 7.3.4.5 Reimbursement scenario
      • 7.3.4.6 India liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.3.5 Australia
      • 7.3.5.1 Key country dynamics
      • 7.3.5.2 Target disease prevalence
      • 7.3.5.3 Competitive scenario
      • 7.3.5.4 Regulatory framework & reimbursement scenario
      • 7.3.5.5 Australia liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.3.6 Thailand
      • 7.3.6.1 Key country dynamics
      • 7.3.6.2 Target disease prevalence
      • 7.3.6.3 Competitive scenario
      • 7.3.6.4 Regulatory framework & reimbursement scenario
      • 7.3.6.5 Thailand liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.3.7 South Korea
      • 7.3.7.1 Key country dynamics
      • 7.3.7.2 Target disease prevalence
      • 7.3.7.3 Competitive scenario
      • 7.3.7.4 Regulatory framework & reimbursement scenario
      • 7.3.7.5 South Korea liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.4 Latin America
    • 7.4.1 SWOT analysis:
      • 7.4.1.1 Latin America liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.4.2 Brazil
      • 7.4.2.1 Key country dynamics
      • 7.4.2.2 Target disease prevalence
      • 7.4.2.3 Competitive scenario
      • 7.4.2.4 Regulatory framework
      • 7.4.2.5 Reimbursement scenario
      • 7.4.2.6 Brazil liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.4.3 Mexico
      • 7.4.3.1 Key country dynamics
      • 7.4.3.2 Target disease prevalence
      • 7.4.3.3 Competitive scenario
      • 7.4.3.4 Regulatory framework
      • 7.4.3.5 Reimbursement scenario
      • 7.4.3.6 Mexico liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.4.4 Argentina
      • 7.4.4.1 Key country dynamics
      • 7.4.4.2 Target disease prevalence
      • 7.4.4.3 Competitive scenario
      • 7.4.4.4 Regulatory framework
      • 7.4.4.5 Reimbursement scenario
      • 7.4.4.6 Argentina liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.5 Middle East & Africa (MEA)
    • 7.5.1 SWOT analysis:
      • 7.5.1.1 Middle East & Africa liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.5.2 South Africa
      • 7.5.2.1 Key Country dynamics
      • 7.5.2.2 Target disease prevalence
      • 7.5.2.3 Competitive scenario
      • 7.5.2.4 Regulatory framework
      • 7.5.2.5 Reimbursement scenario
      • 7.5.2.6 South Africa liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.5.3 Saudi Arabia
      • 7.5.3.1 Key country dynamics
      • 7.5.3.2 Target disease prevalence
      • 7.5.3.3 Competitive scenario
      • 7.5.3.4 Regulatory framework
      • 7.5.3.5 Reimbursement scenario
      • 7.5.3.6 Saudi Arabia liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.5.4 UAE
      • 7.5.4.1 Key country dynamics
      • 7.5.4.2 Target disease prevalence
      • 7.5.4.3 Competitive scenario
      • 7.5.4.4 Regulatory framework
      • 7.5.4.5 Reimbursement scenario
      • 7.5.4.6 UAE liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.5.5 Kuwait
      • 7.5.5.1 Key country dynamics
      • 7.5.5.2 Target disease prevalence
      • 7.5.5.3 Competitive scenario
      • 7.5.5.4 Regulatory framework
      • 7.5.5.5 Reimbursement Scenario
      • 7.5.5.6 Kuwait liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
      • 7.5.5.7 Rest of MEA liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)

Chapter 8 Competitive Landscape

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants
    • 8.1.1 New product launch
    • 8.1.2 Merger and acquisition
    • 8.1.3 Licensing agreements
    • 8.1.4 Conferences and campaigns
  • 8.2 Company Categorization
    • 8.2.1 Innovators
    • 8.2.2 Market leaders
  • 8.3 Vendor Landscape
    • 8.3.1 List of key distributors and channel partners
    • 8.3.2 Key customers
  • 8.4 Public Companies
    • 8.4.1 Key company market share analysis, 2023
    • 8.4.2 Company market position analysis
    • 8.4.3 Heat map analysis
    • 8.4.4 Competitive dashboard analysis
      • 8.4.4.1 Market differentiators
  • 8.5 Private Companies
    • 8.5.1 List of key emerging companies
    • 8.5.2 Regional network map
  • 8.6 Company Profiles
    • 8.6.1. F. Hoffmann-La Roche Ltd.
      • 8.6.1.1 Company overview
      • 8.6.1.2 Financial performance
      • 8.6.1.3 Product benchmarking
      • 8.6.1.4 Strategic initiatives
    • 8.6.2 AstraZeneca
      • 8.6.2.1 Company overview
      • 8.6.2.2 Financial performance
      • 8.6.2.3 Product benchmarking
      • 8.6.2.4 Strategic initiatives
    • 8.6.3 Bayer AG
      • 8.6.3.1 Company overview
      • 8.6.3.2 Financial performance
      • 8.6.3.3 Product benchmarking
      • 8.6.3.4 Strategic initiatives
    • 8.6.4 Eli Lilly and Company
      • 8.6.4.1 Company overview
      • 8.6.4.2 Financial performance
      • 8.6.4.3 Product benchmarking
      • 8.6.4.4 Strategic initiatives
    • 8.6.5 Ono Pharmaceutical
      • 8.6.5.1 Company overview
      • 8.6.5.2 Financial performance
      • 8.6.5.3 Product benchmarking
      • 8.6.5.4 Strategic initiatives
    • 8.6.6 Pfizer, Inc.
      • 8.6.6.1 Company overview
      • 8.6.6.2 Financial performance
      • 8.6.6.3 Product benchmarking
      • 8.6.6.4 Strategic initiatives
    • 8.6.7 Bristol-Myers Squibb Company
      • 8.6.7.1 Company overview
      • 8.6.7.2 Financial performance
      • 8.6.7.3 Product benchmarking
      • 8.6.7.4 Strategic initiatives
    • 8.6.8 Cadila Pharmaceuticals Ltd.
      • 8.6.8.1 Company overview
      • 8.6.8.2 Financial performance
      • 8.6.8.3 Product benchmarking
      • 8.6.8.4 Strategic initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Global Liver Metastases Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 6 Global Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 7 Global Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 North America Liver Metastases Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 10 North America Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 11 North America Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 12 U.S. Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 14 U.S. Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 Canada Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 17 Canada Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 18 Europe Liver Metastases Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 19 Europe Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 20 Europe Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 21 Europe Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 22 Germany Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 23 Germany Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 24 Germany Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 UK Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 26 UK Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 27 UK Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 France Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 29 France Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 30 France Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 31 Italy Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 32 Italy Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 33 Italy Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Spain Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 35 Spain Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 36 Spain Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 Denmark Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 38 Denmark Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 39 Denmark Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Sweden Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 41 Sweden Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 42 Sweden Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 Norway Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 44 Norway Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 45 Norway Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Liver Metastases Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 50 Japan Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 51 Japan Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 52 Japan Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 China Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 54 China Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 55 China Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 India Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 57 India Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 58 India Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 South Korea Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 60 South Korea Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 61 South Korea Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 Australia Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 63 Australia Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 64 Australia Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 Thailand Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 66 Thailand Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 67 Thailand Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 68 Latin America Liver Metastases Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 69 Latin America Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 70 Latin America Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 71 Latin America Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 72 Brazil Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 73 Brazil Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 74 Brazil Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 75 Mexico Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 76 Mexico Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 77 Mexico Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 78 Argentina Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 79 Argentina Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 80 Argentina Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Liver Metastases Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 88 South Africa Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 89 South Africa Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 90 South Africa Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 91 UAE Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 92 UAE Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 93 UAE Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Liver Metastases Treatment Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Information Procurement
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 QFD Modeling For Market Share Assessment
  • Fig. 8 Market Formulation & Validation
  • Fig. 9 Market Snapshot
  • Fig. 10 Segment Snapshot (By Treatment Type, By Primary Cancer, And By Distribution Channel)
  • Fig. 11 Competitive Landscape Snapshot
  • Fig. 12 Penetration & Growth Prospect Mapping For Type, 2023
  • Fig. 13 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 14 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 15 Liver Metastases Treatment Market: Treatment Type Outlook And Key Takeaways
  • Fig. 16 Liver Metastases Treatment Market: Treatment Type Movement Analysis
  • Fig. 17 Chemotherapy Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Targeted Therapy Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Immunotherapy Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Liver Metastases Treatment Market: Primary Cancer Outlook And Key Takeaways
  • Fig. 21 Liver Metastases Treatment Market: Primary Cancer Movement Analysis
  • Fig. 22 Colorectal Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Breast Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Liver Metastases Treatment Market: Distribution Channel Outlook And Key Takeaways
  • Fig. 26 Liver Metastases Treatment Market: Distribution Channel Movement Analysis
  • Fig. 27 Hospital Pharmacies Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Hospital Pharmacies Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Regional Marketplace: Key Takeaways
  • Fig. 30 North America: SWOT Analysis
  • Fig. 31 North America Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. Key Country Dynamics
  • Fig. 33 U.S. Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 34 U.S. Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Canada Key Country Dynamics
  • Fig. 36 Canada Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 37 Canada Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Europe: SWOT Analysis
  • Fig. 39 Europe Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Germany Key Country Dynamics
  • Fig. 41 Germany Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 42 Germany Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 UK Key Country Dynamics
  • Fig. 44 UK Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 45 UK Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 France Key Country Dynamics
  • Fig. 47 France Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 48 France Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Italy Key Country Dynamics
  • Fig. 50 Italy Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 51 Italy Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Spain Key Country Dynamics
  • Fig. 53 Spain Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 54 Spain Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark Key Country Dynamics
  • Fig. 56 Denmark Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 57 Denmark Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Sweden Key Country Dynamics
  • Fig. 59 Sweden Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 60 Sweden Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Norway Key Country Dynamics
  • Fig. 62 Norway Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 63 Norway Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Asia Pacific: SWOT Analysis
  • Fig. 65 Asia Pacific Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Japan Key Country Dynamics
  • Fig. 67 Japan Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 68 Japan Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 China Key Country Dynamics
  • Fig. 70 China Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 71 China Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 India Key Country Dynamics
  • Fig. 73 India Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 74 India Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Australia Key Country Dynamics
  • Fig. 76 Australia Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 77 Australia Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 South Korea Key Country Dynamics
  • Fig. 79 South Korea Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 80 South Korea Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Thailand Key Country Dynamics
  • Fig. 82 Thailand Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 83 Thailand Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Latin America (LATAM): SWOT Analysis
  • Fig. 85 Latin America Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Brazil Key Country Dynamics
  • Fig. 87 Brazil Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 88 Brazil Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Mexico Key Country Dynamics
  • Fig. 90 Mexico Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 91 Mexico Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Argentina Key Country Dynamics
  • Fig. 93 Argentina Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 94 Argentina Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Middle East & Africa (MEA): SWOT Analysis
  • Fig. 96 Middle East & Africa (MEA) Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 South Africa Key Country Dynamics
  • Fig. 98 Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 99 South Africa Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Saudi Arabia Key Country Dynamics
  • Fig. 101 Saudi Arabia Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 102 Saudi Arabia Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 UAE Key Country Dynamics
  • Fig. 104 UAE Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 105 UAE Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Kuwait Key Country Dynamics
  • Fig. 107 Kuwait Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 108 Kuwait Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Heat Map Analysis
  • Fig. 110 Strategic Framework